SUMATRIPTAN

USDailyMed:Sumatriptan N02CC01(WHO) CA:℞-onlyUK:POM(Prescription only) / PUS:℞-onlyIn general: ℞ (Prescription only) 1-[3-(2-Dimethylaminoethyl)-1H-indol-5-yl]-N-methyl-methanesulfonamide 103628-46-2Y 5358 54 DB00669Y 5165Y 8R78F6L9VO D00451Y CHEBI:10650Y ChEMBL128Y DTXSID4023628 Interactive image O=S(=O)(NC)Cc1cc2c(cc1)[nH]cc2CCN(C)C InChI=1S/C14H21N3O2S/c1-15-20(18,19)10-11-4-5-14-13(8-11)12(9-16-14)6-7-17(2)3/h4-5,8-9,15-16H,6-7,10H2,1-3H3YKey:KQKPFRSPSRPDEB-UHFFFAOYSA-NY Sumatriptan, sold under the brand nameImitrexamong others, is amedicationused to treatmigraine headachesandcluster headaches.It is takenorally,intranasally, or bysubcutaneousinjection.Therapeutic effects generally occur within three hours.Sumatriptan is a serotonin (5-HT1B/1D) receptor agonist (triptan). The drug acts as aserotonin5-HT1B,5-HT1D, and5-HT1Freceptoragonistand its common side effects includechest pressure, fatigue, vomiting,tingling, andvertigo. Serious side effects may includeserotonin syndrome,heart attack,stroke, andseizures. With excessive use,medication overuse headachesmay occur.It is unclear if use duringpregnancyorbreastfeedingis safe.Themechanism of actionis not entirely clear. It is in thetriptanclass of medications. Sumatriptan was patented in 1982 and approved for medical use in 1992.It is on theWorld Health Organization's List of Essential Medicines.It is available as ageneric medication.In 2023, it was the 107th most commonly prescribed medication in the United States, with more than 6million prescriptions.It is also available as the combination productsumatriptan/naproxen.